Sponsor Deadline
Posted: 5/14/2024

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

This NOFO utilizes the R61 award mechanism for exploratory/developmental projects. The R61 mechanism is suitable for projects that are at their inception, conceptual, or idea-based phase. In this phase, technical feasibility of the proposed technology or methodology should have not yet been established. Preliminary data are not required but are accepted if available. If preliminary data are sufficient to suggest the feasibility of the approach is established, then consideration should be given to submitting to the companion R33 NOFO (RFA-CA-24-011).

Deadlines:

  • Letters of Intent Receipt Date(s): 30 days before the application due date
  • Application Due Date(s): April 1, 2024; Oct. 1, 2024

RFA-CA-24-010 Expiration Date: October 2, 2024

Amount Description

Application budgets are limited to $150,000 per year (in direct costs).

The total project period request may not exceed 3 years.

Amount
$450,000
Funding Type
Eligibility
Posted
5/14/2024
Deadline
Sponsor: